ABSTRACT
It is for these reasons that, in the case of prostate cancer, comparison between expectant management and definitive treatment is a vitally important issue. Given that it is so important, it is unfortunate that there is such a paucity of quality data comparing the outcome of expectant management with that of definitive treatment. Furthermore, almost all available data relate to cases typical of the pre-prostate-specific antigen (PSA) era, and such data may not be generalizable to contemporary, PSA screen-detected disease.
